Funding isn't exactly thin on the ground at the moment...
SAN DIEGO, Dec. 3 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX - news) today announced that it has priced a public offering of 3,500,000 shares of common stock at a price of $46.75 per share. The company offered all of the 3,500,000 shares. The underwriters have a 30-day option to purchase up to 525,000 additional shares of common stock from the company solely to cover over-allotments, if any.
The joint bookrunning managers for the offering were Deutsche Banc Alex. Brown and Credit Suisse First Boston Corporation. Co-managers of this offering were CIBC World Markets Corp., Lehman Brothers Inc., and UBS Warburg LLC.
PALO ALTO, Calif., Dec. 4 /PRNewswire/ -- CV Therapeutics, Inc. (Nasdaq: CVTX - news) today announced that it has priced a public offering of 2.5 million shares of its common stock at a purchase price of $52.50 per share. All of the shares were offered by CV Therapeutics, Inc. In addition, the Company has granted the underwriters an option to purchase an additional 375,000 shares of common stock to cover over-allotments if any.
J.P. Morgan Securities Inc. and Robertson Stephens, Inc. are acting as joint lead managers of the offering, with J.P. Morgan Securities Inc. as the sole bookrunner. Bear, Stearns & Co. Inc., CIBC World Markets Corp., Morgan Stanley & Co. Incorporated, SG Cowen Securities Corporation, U.S. Bancorp Piper Jaffray Inc., and First Albany Corporation are acting as co-managers.
VICTORIA, BC, Dec. 3 /PRNewswire/ - Stressgen Biotechnologies Corporation (TSE: SSB - news) announced today that it has entered into an agreement with a syndicate of Canadian underwriters, on a bought deal basis, to issue and sell 6,024,100 common shares at a price of Canadian $4.15 per share for gross proceeds of approximately Canadian $25,000,000. The underwriters have an option to purchase up to an additional 2,409,640 common shares on the same terms. The offering is subject to the approval of The Toronto Stock Exchange and all necessary regulatory approvals. The financing is expected to close on or about December 20, 2001.
SEATTLE--(BW HealthWire)--Dec. 4, 2001--Corixa Corporation (Nasdaq:CRXA - news), a developer of immunotherapeutics, today announced that it has entered into an agreement with BNY Capital Markets, Inc., a subsidiary of the Bank of New York, for a $75 million equity line of credit.
BNY has agreed to purchase Corixa common stock at a two percent discount to the market price and the financing will be available to Corixa, subject to certain conditions, at its option on an as-needed basis over a period of 24 months. Subject to certain limitations, Corixa has the right to determine the timing and amount of each sale. Shoreline Pacific, LLC acted as a placement agent on this transaction.
WEST CHESTER, Pa., Dec. 4 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH - news) announced today that it intends to raise $300 million, subject to market and other conditions, and excluding proceeds from the exercise of any option granted to the initial purchasers, through an offering of convertible subordinated notes...
BALTIMORE--(BW HealthWire)--Dec. 4, 2001--New Enterprise Associates (NEA) today announced that it has invested $20 million in Pharmion Corporation.
Pharmion, a global pharmaceutical company, raised $65 million in a private placement financing to further the company's global infrastructure for regulatory affairs, sales, and marketing to support the registration and launch of its first two products...
Pharmion recently signed agreements with Celgene Corporation to expand internationally the THALOMID® (thalidomide) franchise. In June 2001, Pharmion acquired from Pharmacia Corporation global rights to develop and commercialize 5-Azacitidine, a drug that has been studied for the treatment of myelodysplastic syndromes (MDS)... |
